CN101263142A - Raf抑制剂化合物及其使用方法 - Google Patents

Raf抑制剂化合物及其使用方法 Download PDF

Info

Publication number
CN101263142A
CN101263142A CNA2006800266418A CN200680026641A CN101263142A CN 101263142 A CN101263142 A CN 101263142A CN A2006800266418 A CNA2006800266418 A CN A2006800266418A CN 200680026641 A CN200680026641 A CN 200680026641A CN 101263142 A CN101263142 A CN 101263142A
Authority
CN
China
Prior art keywords
alkyl
cancer
compound
heterocycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800266418A
Other languages
English (en)
Chinese (zh)
Inventor
埃伦·莱尔德
乔治·托波拉夫
约瑟夫·P·利西卡托斯
迈克·韦尔奇
乔纳斯·格林纳
乔希·汉森
布雷德·纽豪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Array Biopharma Inc
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CN101263142A publication Critical patent/CN101263142A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2006800266418A 2005-05-20 2006-05-18 Raf抑制剂化合物及其使用方法 Pending CN101263142A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68317505P 2005-05-20 2005-05-20
US60/683,175 2005-05-20

Publications (1)

Publication Number Publication Date
CN101263142A true CN101263142A (zh) 2008-09-10

Family

ID=37432152

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800266418A Pending CN101263142A (zh) 2005-05-20 2006-05-18 Raf抑制剂化合物及其使用方法

Country Status (14)

Country Link
US (1) US7566716B2 (https=)
EP (1) EP1902056A2 (https=)
JP (1) JP2008540674A (https=)
KR (1) KR20080038278A (https=)
CN (1) CN101263142A (https=)
AU (1) AU2006247118A1 (https=)
BR (1) BRPI0610863A2 (https=)
CA (1) CA2609299A1 (https=)
IL (1) IL187509A0 (https=)
MX (1) MX2007014510A (https=)
NO (1) NO20076553L (https=)
RU (1) RU2007147382A (https=)
WO (1) WO2006125101A2 (https=)
ZA (1) ZA200710969B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102406646A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的用途
CN102666498A (zh) * 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
CN116217416A (zh) * 2022-12-31 2023-06-06 黄淮学院 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006028862A1 (de) * 2006-06-23 2007-12-27 Merck Patent Gmbh 3-Amino-imidazo[1,2-a]pyridinderivate
WO2008042639A1 (en) 2006-10-02 2008-04-10 Irm Llc Compounds and compositions as protein kinase inhibitors
US20100298314A1 (en) * 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
CN101855222A (zh) * 2007-05-10 2010-10-06 通用电气健康护理有限公司 对大麻素cb2受体具有活性的咪唑并(1,2-a)吡啶和相关化合物
UY31292A1 (es) * 2007-08-14 2009-03-31 Imidazoles biciclicos fusionados
MX2010001636A (es) * 2007-08-14 2010-03-15 Hoffmann La Roche Derivados de pirazolo[3,4-d]-pirimidina como agentes antiproliferativos.
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
PE20091561A1 (es) * 2008-02-29 2009-10-30 Array Biopharma Inc Compuestos inhibidores de raf y metodos para su uso
ES2392482T3 (es) * 2008-02-29 2012-12-11 Array Biopharma, Inc. Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
JP2011513331A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
WO2010083617A1 (en) 2009-01-21 2010-07-29 Oncalis Ag Pyrazolopyrimidines as protein kinase inhibitors
CN102712646A (zh) 2009-08-28 2012-10-03 阵列生物制药公司 Raf抑制剂化合物及其使用方法
US20130018033A1 (en) 2009-08-28 2013-01-17 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
US20120157453A1 (en) 2009-08-28 2012-06-21 Genentech, Inc. Raf inhibitor compounds and methods of use thereof
WO2011025951A1 (en) 2009-08-28 2011-03-03 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP2470532A1 (en) 2009-08-28 2012-07-04 Array Biopharma, Inc. 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase
KR101233082B1 (ko) 2010-02-25 2013-02-14 주식회사 이큐스앤자루 신규한 이미다졸피라진 유도체 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 항바이러스 치료용 약학적 조성물
BR112012030909A2 (pt) 2010-06-04 2020-08-18 Abraxis Bioscience, Llc métodos de tratamento de câncer pancreático
EP2661434A4 (en) 2011-01-06 2014-07-09 Beta Pharma Canada Inc NEW UREAS FOR THE TREATMENT AND PREVENTION OF CANCER
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
US9273046B2 (en) 2011-12-31 2016-03-01 Beigene, Ltd. Fused tricyclic compounds as Raf kinase inhibitors
US9670231B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic amide compounds as multiple kinase inhibitors
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
EP3046557A1 (en) 2013-09-20 2016-07-27 Stichting Het Nederlands Kanker Instituut Rock in combination with mapk-pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
EP3365340B1 (en) 2015-10-19 2022-08-10 Incyte Corporation Heterocyclic compounds as immunomodulators
US20170145025A1 (en) 2015-11-19 2017-05-25 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2916874T3 (es) 2015-12-17 2022-07-06 Incyte Corp Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1
AU2016379372A1 (en) 2015-12-22 2018-08-02 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2906460T3 (es) 2016-05-06 2022-04-18 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
ES2905980T3 (es) 2016-05-26 2022-04-12 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
BR112018076534A2 (pt) 2016-06-20 2019-04-02 Incyte Corporation compostos heterocíclicos como imunomoduladores
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
ES2899402T3 (es) 2016-12-22 2022-03-11 Incyte Corp Derivados de piridina como inmunomoduladores
EP3558990B1 (en) 2016-12-22 2022-08-10 Incyte Corporation Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers
JP7341060B2 (ja) 2017-02-10 2023-09-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP3732285A1 (en) 2017-12-28 2020-11-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
CR20200520A (es) 2018-03-30 2021-03-09 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2019217821A1 (en) 2018-05-11 2019-11-14 Incyte Corporation Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
EA202191482A1 (ru) * 2018-11-26 2021-12-14 Янссен Сайенсиз Айрлэнд Анлимитед Компани Другие гетероароматические соединения, обладающие активностью против rsv
EP4010342A1 (en) 2019-08-09 2022-06-15 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
WO2021067217A1 (en) 2019-09-30 2021-04-08 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
BR112022009031A2 (pt) 2019-11-11 2022-10-11 Incyte Corp Sais e formas cristalinas de um inibidor de pd-1/pd-l1
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
US11866434B2 (en) 2020-11-06 2024-01-09 Incyte Corporation Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203052A3 (en) * 1999-10-08 2004-06-28 Gruenenthal Gmbh Bicyclic imidazo-3-yl-amine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
DE10019714A1 (de) * 2000-04-20 2002-01-10 Gruenenthal Gmbh Salze von bicyclischen, N-acylierten Imidazo-3-aminen und Imidazo-5-aminen
DE10050663A1 (de) * 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
AU2002224927A1 (en) * 2000-12-13 2002-06-24 Basf Aktiengesellschaft Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
TWI312347B (en) * 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
GB0112348D0 (en) * 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
DE10150172A1 (de) 2001-10-11 2003-04-30 Morphochem Ag Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2005120513A1 (en) 2004-06-09 2005-12-22 Oncalis Ag Protein kinase inhibitors
DE102004044884A1 (de) 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666498A (zh) * 2009-08-28 2012-09-12 健泰科生物技术公司 Raf抑制剂化合物及其使用方法
CN102406646A (zh) * 2010-09-20 2012-04-11 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的用途
CN102406646B (zh) * 2010-09-20 2015-09-09 北大方正集团有限公司 芳基脲衍生物用于制备治疗移植排斥药物的用途
CN116217416A (zh) * 2022-12-31 2023-06-06 黄淮学院 一种苯并咪唑类药物中间体3-硝基-4-乙基氨基苯甲醇的制备方法

Also Published As

Publication number Publication date
MX2007014510A (es) 2008-02-05
AU2006247118A1 (en) 2006-11-23
WO2006125101A2 (en) 2006-11-23
JP2008540674A (ja) 2008-11-20
US7566716B2 (en) 2009-07-28
US20060281751A1 (en) 2006-12-14
NO20076553L (no) 2008-02-19
KR20080038278A (ko) 2008-05-06
CA2609299A1 (en) 2006-11-23
ZA200710969B (en) 2009-03-25
EP1902056A2 (en) 2008-03-26
IL187509A0 (en) 2008-03-20
RU2007147382A (ru) 2009-06-27
WO2006125101A3 (en) 2007-03-29
BRPI0610863A2 (pt) 2010-08-03

Similar Documents

Publication Publication Date Title
CN101263142A (zh) Raf抑制剂化合物及其使用方法
JP6312634B2 (ja) ピラゾロピリミジンｊａｋ阻害剤化合物及び方法
US7491829B2 (en) RAF inhibitor compounds and methods
RU2537945C2 (ru) Триазиновые, пиримидиновые и пиридиновые аналоги и их применение в качестве терапевтических агентов и диагностических проб
JP5769199B2 (ja) ピラゾロピリミジンｊａｋ阻害剤化合物と方法
JP5736171B2 (ja) チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5689069B2 (ja) ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
JP2009526761A (ja) ヘテロ二環式チオフェン化合物および使用の方法
KR20080052630A (ko) Ｒａｆ 억제제 화합물 및 그의 사용 방법
JP2010538094A (ja) チロシンキナーゼ阻害剤としてのピラゾロピリジン類
JP2009529047A (ja) ヘテロ二環系ピラゾール化合物およびその使用
KR20140139023A (ko) 암을 치료하기 위한 6-(4-(1-아미노-3-하이드록시사이클로부틸)페닐)-5-페닐(퓨로, 싸이에노 또는 피롤로)[2,3-d]피리미딘-4-온 유도체
CN103748095A (zh) 二环杂芳族化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20080910

C20 Patent right or utility model deemed to be abandoned or is abandoned